Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of NK105 in previously treated advanced or recurrent gastric cancer
jRCT2080220741Phase 2
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jun 2009
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NK105 in gastric cancer (GC), sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
NK105
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080220741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220741.